465 related articles for article (PubMed ID: 24600203)
21. An update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive review.
McNally TW; Damato EM; Murray PI; Denniston AK; Barry RJ
Orphanet J Rare Dis; 2017 Jul; 12(1):130. PubMed ID: 28716038
[TBL] [Abstract][Full Text] [Related]
22. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis.
Oray M; Tuğal-Tutkun İ
Turk J Ophthalmol; 2016 Apr; 46(2):77-82. PubMed ID: 27800265
[TBL] [Abstract][Full Text] [Related]
24. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
25. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
[TBL] [Abstract][Full Text] [Related]
26. Biologics in the Treatment of Uveitis.
Dingerkus VLS; Becker MD; Doycheva D
Klin Monbl Augenheilkd; 2022 May; 239(5):686-694. PubMed ID: 35426112
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report.
Halilbasic M; Vodencarevic AN; Cosickic A; Halilbasic A; Cabric A
Mater Sociomed; 2021 Mar; 33(1):78-81. PubMed ID: 34012357
[TBL] [Abstract][Full Text] [Related]
28. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
29. Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.
Sánchez-Cano D; Callejas-Rubio JL; Ruiz-Villaverde R; Ríos-Fernández R; Ortego-Centeno N
Mediators Inflamm; 2013; 2013():286857. PubMed ID: 23983404
[TBL] [Abstract][Full Text] [Related]
30. Early administration of adalimumab for paediatric uveitis due to Behçet's disease.
Hiyama T; Harada Y; Doi T; Kiuchi Y
Pediatr Rheumatol Online J; 2019 Jun; 17(1):29. PubMed ID: 31182107
[TBL] [Abstract][Full Text] [Related]
31. A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis.
S Mehta N; Emami-Naeini P
J Ophthalmic Vis Res; 2022; 17(2):276-289. PubMed ID: 35765634
[TBL] [Abstract][Full Text] [Related]
32. Advancements in the management of uveitis.
Schwartzman S
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):304-315. PubMed ID: 27886802
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
34. Perspectives for immunotherapy in noninfectious immune mediated uveitis.
Touhami S; Gueudry J; Leclercq M; Touitou V; Ghembaza A; Errera MH; Saadoun D; Bodaghi B
Expert Rev Clin Immunol; 2021 Sep; 17(9):977-989. PubMed ID: 34264142
[No Abstract] [Full Text] [Related]
35. [Immunosuppressive therapy in severe or chronic pediatric uveitis: Review of the literature].
Stolowy N; Zanin E; Comet A; Jurquet AL; Benso C; Matonti F; Retornaz K; Kaplanski G; Denis D
J Fr Ophtalmol; 2021 Feb; 44(2):252-258. PubMed ID: 33423814
[TBL] [Abstract][Full Text] [Related]
36. Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India.
Sadhu S; Dutta Majumder P; Biswas J
Indian J Ophthalmol; 2020 Sep; 68(9):1929-1933. PubMed ID: 32823417
[TBL] [Abstract][Full Text] [Related]
37. Biologics in the treatment of uveitis.
Imrie FR; Dick AD
Curr Opin Ophthalmol; 2007 Nov; 18(6):481-6. PubMed ID: 18163000
[TBL] [Abstract][Full Text] [Related]
38. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II.
Lee K; Bajwa A; Freitas-Neto CA; Metzinger JL; Wentworth BA; Foster CS
Expert Opin Biol Ther; 2014 Nov; 14(11):1651-66. PubMed ID: 25226284
[TBL] [Abstract][Full Text] [Related]
39. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
40. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
